Abstract
Malignant melanoma represents one of the most aggressive malignancies but outcome is highly variable with early tumor lesions having an excellent prognosis following resection. We review here the data on identification of genes involved in the progression of melanoma as a result of expression array studies, genomic profiling, and genetic models. We focus on the role of tumor suppressors involved in cell cycle function, DNA repair, and genome maintenance. Highlighted are the roles of loss of p16 in promoting neoplasia in cooperation with deregulated MAPK signaling, and the role of loss of the RASSF1A protein in promoting chromosomal instability. The interactions between point mutation in growth signaling molecules and epigenetic changes in genes involved in DNA repair and cell division are discussed.
Keywords: Melanoma, genetic progression, tumor suppressors, cell cycle, alkylating agents, mitotic spindle, mitotic spindle poisons
Current Genomics
Title: Molecular Markers of Tumor Progression in Melanoma
Volume: 10 Issue: 4
Author(s): Joshua Rother and Dan Jones
Affiliation:
Keywords: Melanoma, genetic progression, tumor suppressors, cell cycle, alkylating agents, mitotic spindle, mitotic spindle poisons
Abstract: Malignant melanoma represents one of the most aggressive malignancies but outcome is highly variable with early tumor lesions having an excellent prognosis following resection. We review here the data on identification of genes involved in the progression of melanoma as a result of expression array studies, genomic profiling, and genetic models. We focus on the role of tumor suppressors involved in cell cycle function, DNA repair, and genome maintenance. Highlighted are the roles of loss of p16 in promoting neoplasia in cooperation with deregulated MAPK signaling, and the role of loss of the RASSF1A protein in promoting chromosomal instability. The interactions between point mutation in growth signaling molecules and epigenetic changes in genes involved in DNA repair and cell division are discussed.
Export Options
About this article
Cite this article as:
Rother Joshua and Jones Dan, Molecular Markers of Tumor Progression in Melanoma, Current Genomics 2009; 10 (4) . https://dx.doi.org/10.2174/138920209788488526
DOI https://dx.doi.org/10.2174/138920209788488526 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on Chemical Profile of Coumarins and their Therapeutic Role in the Treatment of Cancer
Current Drug Delivery Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Acridone-based Antitumor Agents: A Mini-review
Anti-Cancer Agents in Medicinal Chemistry Regulation of Innate Immune Responses in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Inhibitory Effect of Sesamolin on Melanogenesis in B16F10 Cells Determined by In Vitro and Molecular Docking Analyses
Current Pharmaceutical Biotechnology Anticancer Drug Sensitivity Testing, a Historical Review and Future Perspectives
Current Drug Therapy Drug Resistance: Challenges to Effective Therapy
Current Cancer Drug Targets Regulation of Cell Growth by Estrogen Signaling and Potential Targets in Thyroid Cancer
Current Cancer Drug Targets Synergistic Effects of Linderanolide B Combined with Arbutin, PTU or Kojic Acid on Tyrosinase Inhibition
Current Pharmaceutical Biotechnology Cellular Senescence and Anti-Cancer Therapy
Current Drug Targets Folate Receptor Targeted Liposomes Encapsulating Anti-Cancer Drugs
Current Pharmaceutical Biotechnology Human Sirtuins: An Overview of an Emerging Drug Target in Age-Related Diseases and Cancer
Current Drug Targets Targeting Cancer Cells with Photoactive Silica Nanoparticles
Current Pharmaceutical Design Evaluation of Ocular Irritation and Bioavailability of Voriconazole Loaded Microemulsion
Current Drug Delivery Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Synthesis, Biological Activity of Thiazolidinones Bearing Indoline Moiety and Isatin Based Hybrids
Mini-Reviews in Organic Chemistry The Function of the Selective Inhibitors of Cycloxygenase 2
Mini-Reviews in Medicinal Chemistry The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Glycosylated Antitumor Ether Lipids: Activity and Mechanism of Action
Anti-Cancer Agents in Medicinal Chemistry Angiogenesis as a therapeutic target in breast cancer
Mini-Reviews in Medicinal Chemistry